TICKERNERD
Menu
NGNENGNEHealthcare · Biotechnology

NGNE Stock Forecast: Neurogene, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$35
−1.77% on the day

The 9 Wall Street analysts covering Neurogene, Inc. hold a median 12-month price target of $65 — +83.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 60 of 100 as at 10 Sept 2026 — in the upper half.

Market cap
$722.8M
Ticker Nerd rank
60 / 100
Median analyst target
$65
Analysts covering
9
Revenue$0.0
Operating income−$36.7M
Net income−$34.5M
Free cash flow−$24.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−5.7%
1M
−0.9%
YTD
+72.2%
1Y
+76.7%
From 52W high
−17.2%
From 52W low
+116.7%
$16
$43
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

NGNE stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Neurogene, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 10 Sept 2026
60 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
83
Issuance
82
Accruals
78
Value
54
Size
49
Quality
48
Revisions
46
Growth
27
Volatility
22

Momentum (83): The shares have been drifting up relative to others.

Volatility (22): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

NGNE stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on NGNE, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$50$100$150Oct 25Jan 26Apr 26Jul 26NGNEHigh $166Median $65Low $46

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says9 analysts
9 Buy0 Hold0 Sell
Low $46Median $65High $166

The green dot is the last close — the median target sits +83.2% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
12 Aug 2026Canaccord GenuityMaintainsBuy$180 → $166
12 Aug 2026GuggenheimMaintainsBuy$69 → $81
12 Aug 2026HC Wainwright & Co.MaintainsBuy$70 → $65
9 June 2026HC Wainwright & Co.ReiteratesBuy$70
9 June 2026HC Wainwright & Co.ReiteratesBuy—
6 Apr 2026Canaccord GenuityMaintainsBuy—
27 Feb 2026Canaccord GenuityInitiatesBuy—
26 Jan 2026LifeSci CapitalInitiatesOutperform—
13 Jan 2026HC Wainwright & Co.ReiteratesBuy—
13 Nov 2025HC Wainwright & Co.MaintainsBuy—
31 Oct 2025HC Wainwright & Co.MaintainsBuy—
9 Oct 2025HC Wainwright & Co.ReiteratesBuy—
17 June 2025Craig-HallumInitiatesBuy—
12 June 2025BMO CapitalMaintainsOutperform—
20 May 2025BMO CapitalMaintainsOutperform—
16 May 2025BairdDowngradeNeutral—
13 May 2025HC Wainwright & Co.MaintainsBuy—
14 Apr 2025BMO CapitalMaintainsOutperform—
25 Mar 2025BairdMaintainsOutperform—
25 Mar 2025HC Wainwright & Co.MaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NGNE appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

NGNE vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Neurogene, Inc. returned +76.7% against +17.5% for the S&P 500, dividends included.

NGNE vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160180200Oct 25Jan 26Apr 26Jul 26NGNES&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

NGNE analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
3
Fundamentals

Neurogene, Inc. (NGNE) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−8.4×

Cheaper than 92% of US stocks

Price / sales
—
Price / book
2.6×

Cheaper than 35% of US stocks

EV / EBITDA
−4.3×

Cheaper than 78% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−45.3%

Higher than 23% of US stocks

Return on assets
−28.0%

Higher than 15% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Neurogene, Inc. (NGNE) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Neurogene, Inc. has a market value of $722.8M and an enterprise value of $505.8M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$111.1M.

  • Free cash flow in the twelve months to 30 June 2026: −$87.7M.

  • Shares outstanding: 15.8M.

  • Trailing P/E: −8.4×; forward P/E: −6.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Neurogene, Inc. employs 131 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 11 Sept 2026

Data provided by Twelve Data

Peers

NGNE vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
NGNENeurogene, Inc.$722.8M
60
ZVRAZevra Therapeutics, Inc.$708.1M
98
NVCTNuvectis Pharma, Inc.$709.0M
67
MDXGMiMedx Group, Inc.$683.4M
75
SGMTSagimet Biosciences, Inc.$676.7M
35
CBIOCrescent Biopharma, Inc.$719.2M
57
AURAAura Biosciences, Inc.$722.7M
41

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Neurogene, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest NGNE news & analysis

Neurogene to Participate in H.C. Wainwright 28th Annual Global Investment Conference

Business Wire · 8 Sept 2026neutral

Neurogene Inc. announced that its management will participate in the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, including a fireside chat and investor meetings. A live webcast of the fireside chat will be accessible.

Why it matters — The company's participation provides NGNE watchers an opportunity to hear from management and engage in investor meetings at a major investment conference.

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire · 4 Sept 2026neutral

Neurogene's Compensation Committee approved the grant of non-qualified stock options to purchase an aggregate of 38,330 shares of common stock to two new employees on September 1, 2026, as inducement grants under Nasdaq Listing Rule 5635(c)(4).

Why it matters — NGNE watchers would care because this discloses a routine equity-based compensation action tied to hiring, which is a standard administrative disclosure rather than a reflection of company performance.

Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates

Business Wire · 11 Aug 2026positive

Neurogene (Nasdaq: NGNE) reported its second quarter 2026 financial results and highlighted recent corporate updates, including positive long-term Phase 1/2 data for its NGN-401 program that showed durable, multidomain developmental gains for patients with rare neurological diseases.

Why it matters — NGNE watchers will care because the reported Phase 1/2 data for NGN-401 suggest durable clinical progress in the company's lead program targeting rare neurological conditions.

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire · 4 Aug 2026neutral

Neurogene announced that its Compensation Committee approved inducent grants of non-qualified stock options to purchase an aggregate of 12,555 shares of common stock for four new employees, with a grant date of August 3, 2026, under Nasdaq Listing Rule 5635(c)(4).

Why it matters — NGNE watchers would care because inducement stock-option grants are a standard mechanism the company uses to attract and retain new hires, providing insight into its equity-compensation activity without signaling any change in its clinical or financial outlook.

FAQ

Frequently asked questions about NGNE stock

What is the NGNE stock price forecast for 2026-2027?

The 9 Wall Street analysts covering Neurogene, Inc. have a median 12-month price target of $65, with estimates ranging from $46 to $166. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is NGNE stock a buy right now?

Of the 9 analysts covering Neurogene, Inc., 9 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Neurogene, Inc. 60 out of 100 across roughly 4,600 US stocks as at 10 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank NGNE?

As at 10 Sept 2026, Neurogene, Inc. ranks 60 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (83 of 100).

Will NGNE stock go up?

No one can know that. What the data says: the median 12-month target from 9 analysts implies +83.2% from the last close, and Ticker Nerd's factor model ranks Neurogene, Inc. 60 out of 100 as at 10 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the NGNE stock forecast for 2030?

No analyst covering Neurogene, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NGNE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $46 to $166 over the next 12 months.

How has NGNE stock performed over the past year?

Neurogene, Inc. returned +76.7% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Neurogene, Inc. do?

Neurogene Inc. is a clinical-stage biotechnology company focused on developing genetic medicines for rare neurological diseases.

What is the latest news on NGNE?

The most recent item we track (Business Wire, 8 Sept 2026): "Neurogene to Participate in H.C. Wainwright 28th Annual Global Investment Conference". Neurogene Inc. announced that its management will participate in the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, including a fireside chat and investor meetings. A live webcast of the fireside chat will be accessible.

Company

About Neurogene, Inc.

Neurogene Inc. is a clinical-stage biotechnology company focused on developing genetic medicines for rare neurological diseases. Its current pipeline centers on gene therapy programs designed to address severe disorders such as Rett syndrome and CLN5 Batten disease, with candidates that use adeno-associated virus delivery and proprietary transgene regulation technology to control gene expression in the central nervous system. Neurogene’s work is aimed at treating conditions with significant unmet medical need, where conventional approaches have limited impact on the underlying cause of disease. The company also operates gene therapy manufacturing capabilities to support clinical development and production of its programs. Headquartered in New York, Neurogene Inc. is part of the broader biotechnology and rare-disease therapeutics market, where it contributes to the advancement of precision genetic medicine for devastating neurological disorders.

CEO Dr. Rachel L. McMinn Ph.D. · 131 employees · United States · https://www.neurogene.com